|
|
||||||||
Molecular Diagnostics and Genetics |
1 Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, NSW 2050, Australia.
aAuthor for correspondence. Fax 61-2-9515-7931; e-mail peter.stewart{at}email.cs.nsw.gov.au.
Background: Measurement of plasma butyrylcholinesterase (BChE) activity and inhibitor-based phenotyping are standard methods for identifying patients who experience post-succinylcholine (SC) apnea attributable to inherited variants of the BChE enzyme. Our aim was to develop PCR-based assays for BCHE mutation detection and implement them for routine diagnostic use at a university teaching hospital.
Methods: Between 1999 and 2002, we genotyped 65 patients referred after prolonged post-SC apnea. Five BCHE gene mutations were analyzed. Competitive oligo-priming (COP)-PCR was used for flu-1, flu-2, and K-variant and direct DNA sequencing analysis for dibucaine and sil-1 mutations. Additional DNA sequencing of BCHE coding regions was provided when the five-mutation screen was negative or mutation findings were inconsistent with enzyme activity.
Results: Genotyping identified 52 patients with primary hypocholinesterasemia attributable to BCHE mutations, and in 44 individuals the abnormalities were detected by the five-mutation screen (detection rate, 85%). Additional sequencing studies revealed mutations in eight other patients, including five with novel mutations. The most common genotype abnormality was compound homozygous dibucaine and homozygous K-variant mutations. No simple homozygotes were found. Of the remaining 13 patients, 3 had normal BChE activity and gene, and 10 were diagnosed with hypocholinesterasemia unrelated to BCHE gene abnormalities.
Conclusion: A five-mutation screen for investigation of post-SC apnea identified BCHE gene abnormalities for 80% of a referral population. Six new BCHE mutations were identified by sequencing studies of 16 additional patients.
The following articles in journals at HighWire Press have cited this article:
![]() |
S. Levano, D. Keller, E. Schobinger, A. Urwyler, and T. Girard Rapid and Accurate Detection of Atypical and Kalow Variants in the Butyrylcholinesterase Gene Using Denaturing High Performance Liquid Chromatography Anesth. Analg., January 1, 2008; 106(1): 147 - 151. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Valle, D. T. O'Connor, P. Taylor, G. Zhu, G. W. Montgomery, P. E. Slagboom, N. G. Martin, and J. B. Whitfield Butyrylcholinesterase: Association with the Metabolic Syndrome and Identification of 2 Gene Loci Affecting Activity Clin. Chem., June 1, 2006; 52(6): 1014 - 1020. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. De Jaco, D. Comoletti, Z. Kovarik, G. Gaietta, Z. Radic, O. Lockridge, M. H. Ellisman, and P. Taylor A Mutation Linked with Autism Reveals a Common Mechanism of Endoplasmic Reticulum Retention for the {alpha},beta-Hydrolase Fold Protein Family J. Biol. Chem., April 7, 2006; 281(14): 9667 - 9676. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |